Lercanidipine Hydrochloride
At latest update no published data were found on excretion into breast milk.
Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.
Its high plasma protein binding capacity makes it unlikely any passage to the milk, however, its high lipid solubility facilitates excretion into it.
Although it has a low oral bioavailability, it may increase to four times if administered with a fatty meal, which would increase the oral absorption in the infant.
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.
Alternatives
- Nimodipine (Very Low Risk)
- Nifedipine (Very Low Risk)
- Verapamil Hydrochloride (Very Low Risk)
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Synonyms
- Masnidipine
Writings
- Λερκανιδιπίνη Υδροχλωρική (Greek)
- Лерканидипина Гидрохлорид (Cyrillic)
- 塩酸レルカニジピン (Japanese)
- C36H41N3O6,HCl (Molecular formula)
Drug trade names
References
- ARTG. Lercanidipine. Product Monograph. 2014 Full text (in our servers)
- AEMPS. Lercanidipino. Ficha técnica. 2011 Full text (in our servers)